{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Samrotamab_Vedotin",
  "nciThesaurus": {
    "casRegistry": "2052649-42-8",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against a tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of ABBV-085 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.",
    "fdaUniiCode": "SY5HF6N5MB",
    "identifier": "C124134",
    "preferredName": "Samrotamab Vedotin",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129823",
      "C1512"
    ],
    "synonyms": [
      "ABBV-085",
      "ADC ABBV-085",
      "PR-1498487 PAB-MMAE",
      "SAMROTAMAB VEDOTIN",
      "Samrotamab Vedotin"
    ]
  }
}